Our Approach

Bolt is pioneering a new category of targeted immunotherapies that leverage the precision of antibody targeting with the activation of the innate and adaptive immune systems in the tumor microenvironment.

Understand Our Science

Patients

BDC-1001 is a HER2 Boltbody™ ISAC that is currently in clinical development for the treatment of patients with HER2 positive colorectal, endometrial, gastroesophageal, and metastatic breast cancer.

LEARN ABOUT OUR CLINICAL TRIALS

Our Team

Bolt is a world-class, inclusive community of fearless innovators committed to delivering transformative treatments to cancer patients with unmet medical needs.

MEET OUR TEAM

Our Approach

Bolt is pioneering a new category of targeted immunotherapies that leverage the precision of antibody targeting with the activation of the innate and adaptive immune systems in the tumor microenvironment.

Understand Our Science

Patients

BDC-1001 is a HER2 Boltbody™ ISAC that is currently in clinical development for the treatment of patients with HER2 positive colorectal, endometrial, gastroesophageal, and metastatic breast cancer.

LEARN ABOUT OUR CLINICAL TRIALS

Our Team

Bolt is a world-class, inclusive community of fearless innovators committed to delivering transformative treatments to cancer patients with unmet medical needs.

MEET OUR TEAM

Pipeline

Utilizing our Boltbody™ ISAC approach and myeloid biology expertise, we have a built a robust pipeline of immune-stimulating, myeloid-engaging therapeutics.

Program
(Target)IndicationDiscoveryPreclinicalPhase 1Phase 2
Proprietary Development Programs
BDC-1001
HER2

HER2+ Colorectal, Endometrial, Gastroesophageal Cancer

HER2+ Metastatic Breast Cancer*

Phase 2

Monotherapy & nivolumab† combination studyMono and nivolumab combination†

Phase 2

Monotherapy & pertuzumab§ combination studyMono and pertuzumab combination§

Human epidermal growth factor receptor 2, or HER2, is a gene that encodes a protein that promotes cell growth and differentiation. HER2 protein overexpression and gene amplification have been documented across multiple cancers. Previous targeting of HER2 has had a major impact on the subset of patients with HER2-expressing breast and gastric cancer, but there remains a significant amount of work to be done highlighted by a significant individual and global patient need.

Our lead product candidate, BDC-1001, currently advancing into a Phase 2 clinical trial, seeks to improve therapeutic outcomes for patients with HER2-positive colorectal, endometrial, gastroesophageal and metastatic breast cancer.

BDC-3042
Dectin-2

Range of Solid Tumors

Preclinical

IND-enabling activities

Our Myeloid Modulator Platform reawakens myeloid cells to attack tumor cells. We identified monoclonal antibodies that are capable of binding to and agonizing a novel cell surface protein (referred to as Dectin-2) on tumor-supportive macrophages. The activation of these macrophages results in the production of pro-inflammatory cytokines, consistent with the characteristics of tumor-destructive macrophages. Dectin-2 may have the potential to reprogram tumor-supportive macrophages into tumor-destructive macrophages to elicit a productive anti-tumor immune response.

Next-Gen ISAC
Undisclosed

Range of Solid Tumors

Discovery

Discovery
Next-generation Boltbody™ ISAC Collaborations

Genmab

Bispecific Boltbody ISACs
Undisclosed

Discovery

Innovent

Boltbody ISACs
Undisclosed

Discovery

Toray

Boltbody ISAC
Undisclosed

Discovery

* Previously treated with Enhertu
† Collaboration using Bristol-Myers Squibb’s PD-1 inhibitor nivolumab
§ Collaboration using Roche’s HER2 antagonist pertuzumab

*Dectin-2, also known as TAM1

© 2023 - Bolt Biotherapeutics - All rights reserved.